MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
LENSAR Retained Earnings 2011-2026 | LNSR
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings LENSAR
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -178 M | -143 M | -112 M | -97.5 M | -77.6 M | -58 M | -38.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -38.2 M | -178 M | -101 M |
Quarterly Retained Earnings LENSAR
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -176 M | -172 M | -171 M | -143 M | -125 M | -123 M | - | -112 M | -108 M | -111 M | -102 M | -97.5 M | -95 M | -91 M | -84.3 M | -77.6 M | -73.7 M | -67.5 M | -63.2 M | -58 M | -58 M | -58 M | -58 M | -38.2 M | -38.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -38.2 M | -176 M | -95.9 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Bruker Corporation
BRKR
|
2.41 B | $ 36.74 | - | $ 5.47 K |  USA |
 |
ClearPoint Neuro
CLPT
|
-217 M | $ 9.38 | - | $ 266 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
-600 M | - | -26.83 % | $ 2.62 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-312 M | $ 0.59 | - | $ 36.7 M | USA |
 |
AdaptHealth Corp.
AHCO
|
-633 M | $ 12.07 | - | $ 1.63 B | USA |
 |
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Delcath Systems
DCTH
|
-529 M | $ 9.7 | - | $ 347 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-63.5 M | $ 3.45 | 1.77 % | $ 129 M |  France |
 |
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
14.2 B | $ 81.19 | - | $ 47.5 B | USA |
 |
FONAR Corporation
FONR
|
-33.6 M | $ 18.6 | - | $ 122 M | USA |
 |
Globus Medical
GMED
|
1.39 B | $ 88.6 | - | $ 12 B | USA |
 |
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | USA |
 |
Helius Medical Technologies
HSDT
|
-160 M | $ 1.9 | - | $ 1.15 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
940 M | $ 9.31 | - | $ 717 M | USA |
 |
Inspire Medical Systems
INSP
|
-146 M | $ 54.14 | - | $ 1.59 B | USA |
 |
IRIDEX Corporation
IRIX
|
-92.4 M | $ 1.0 | - | $ 16.9 M | USA |
 |
Integer Holdings Corporation
ITGR
|
994 M | $ 85.63 | - | $ 2.97 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-275 M | $ 15.94 | - | $ 374 M | USA |
 |
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | USA |
 |
Medtronic PLC
MDT
|
31.5 B | $ 86.28 | - | $ 111 B | USA |
 |
Align Technology
ALGN
|
2.48 B | $ 171.87 | - | $ 12.9 B | USA |
 |
Myomo
MYO
|
-119 M | $ 0.7 | - | $ 29.3 M | USA |
 |
AxoGen
AXGN
|
-307 M | $ 32.64 | - | $ 1.5 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | USA |
 |
Orthofix Medical
OFIX
|
-368 M | $ 11.77 | - | $ 466 M |  Curacao |
 |
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | USA |
 |
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Penumbra
PEN
|
238 M | $ 329.87 | - | $ 12.8 B | USA |
 |
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-395 M | - | - | $ 111 M |  Canada |
 |
Insulet Corporation
PODD
|
287 M | $ 203.5 | - | $ 14.3 B | USA |
 |
Sintx Technologies
SINT
|
-292 M | $ 2.53 | 0.4 % | $ 7.02 M | USA |
 |
Butterfly Network
BFLY
|
-802 M | $ 4.13 | -0.24 % | $ 874 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | USA |
 |
Smith & Nephew plc
SNN
|
4.96 B | $ 32.63 | - | $ 23.8 B |  Britain |
 |
Stryker Corporation
SYK
|
20.5 B | $ 332.3 | - | $ 127 B | USA |
 |
Tactile Systems Technology
TCMD
|
54.9 M | $ 24.57 | - | $ 562 M | USA |
 |
TELA Bio
TELA
|
-398 M | $ 0.63 | 5.47 % | $ 29.6 M | USA |
 |
TransMedics Group
TMDX
|
-278 M | $ 104.8 | - | $ 3.56 B | USA |
 |
Tandem Diabetes Care
TNDM
|
-1.25 B | $ 19.17 | - | $ 1.3 B | USA |
 |
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | USA |
 |
BioSig Technologies
BSGM
|
-718 M | - | 37.08 % | $ 85.7 M | USA |